1.83 USD
-0.1 (-5.18%)
Last: Jan 30, 2026, 04:30 PM
MGNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While MGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. MGNX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- MGNX had negative earnings in the past year.
- In the past year MGNX has reported a negative cash flow from operations.
- MGNX had negative earnings in each of the past 5 years.
- MGNX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a decent Return On Assets value of -27.68%, MGNX is doing good in the industry, outperforming 68.95% of the companies in the same industry.
- MGNX has a Return On Equity (-111.94%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.68% | ||
| ROE | -111.94% | ||
| ROIC | N/A |
ROA(3y)-23.77%
ROA(5y)-33.17%
ROE(3y)-49.35%
ROE(5y)-55.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MGNX has a better Gross Margin (75.41%) than 84.00% of its industry peers.
- In the last couple of years the Gross Margin of MGNX has declined.
- MGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for MGNX has been increased compared to 1 year ago.
- MGNX has more shares outstanding than it did 5 years ago.
- MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -6.08, we must say that MGNX is in the distress zone and has some risk of bankruptcy.
- MGNX's Altman-Z score of -6.08 is on the low side compared to the rest of the industry. MGNX is outperformed by 63.24% of its industry peers.
- There is no outstanding debt for MGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.08 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 5.27 indicates that MGNX has no problem at all paying its short term obligations.
- MGNX's Current ratio of 5.27 is in line compared to the rest of the industry. MGNX outperforms 58.10% of its industry peers.
- A Quick Ratio of 5.07 indicates that MGNX has no problem at all paying its short term obligations.
- MGNX has a Quick ratio of 5.07. This is comparable to the rest of the industry: MGNX outperforms 58.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.27 | ||
| Quick Ratio | 5.07 |
3. Growth
3.1 Past
- MGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.05%, which is quite impressive.
- Looking at the last year, MGNX shows a decrease in Revenue. The Revenue has decreased by -9.70% in the last year.
- Measured over the past years, MGNX shows a quite strong growth in Revenue. The Revenue has been growing by 18.49% on average per year.
EPS 1Y (TTM)24.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
Revenue 1Y (TTM)-9.7%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%-34.21%
3.2 Future
- MGNX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.98% yearly.
- Based on estimates for the next years, MGNX will show a very negative growth in Revenue. The Revenue will decrease by -12.53% on average per year.
EPS Next Y-14.09%
EPS Next 2Y-31.47%
EPS Next 3Y-25.51%
EPS Next 5Y-4.98%
Revenue Next Year-23.4%
Revenue Next 2Y-38.58%
Revenue Next 3Y-27.41%
Revenue Next 5Y-12.53%
3.3 Evolution
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- MGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGNX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as MGNX's earnings are expected to decrease with -25.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.47%
EPS Next 3Y-25.51%
5. Dividend
5.1 Amount
- No dividends for MGNX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MACROGENICS INC / MGNX FAQ
Can you provide the ChartMill fundamental rating for MACROGENICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to MGNX.
What is the valuation status of MACROGENICS INC (MGNX) stock?
ChartMill assigns a valuation rating of 0 / 10 to MACROGENICS INC (MGNX). This can be considered as Overvalued.
What is the profitability of MGNX stock?
MACROGENICS INC (MGNX) has a profitability rating of 2 / 10.
How financially healthy is MACROGENICS INC?
The financial health rating of MACROGENICS INC (MGNX) is 6 / 10.
Can you provide the expected EPS growth for MGNX stock?
The Earnings per Share (EPS) of MACROGENICS INC (MGNX) is expected to decline by -14.09% in the next year.